Acadia Pharmaceuticals Inc’s filing revealed that its EVP, COO, HEAD OF COMMERCIAL Teehan Brendan unloaded Company’s shares for reported $0.17 million on Nov 19 ’24. In the deal valued at $16.81 per share,10,329 shares were sold. As a result of this transaction, Teehan Brendan now holds 62,105 shares worth roughly $1.07 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Kihara James sold 4,073 shares, generating $68,467 in total proceeds. Upon selling the shares at $16.81, the PRINCIPAL ACCOUNTING OFFICER now owns 19,863 shares.
Before that, Schneyer Mark C. sold 10,259 shares. Acadia Pharmaceuticals Inc shares valued at $172,454 were divested by the EVP, CHIEF FINANCIAL OFFICER at a price of $16.81 per share. As a result of the transaction, Schneyer Mark C. now holds 53,302 shares, worth roughly $0.92 million.
A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who decreased its forecast for the stock in early August from “an Overweight” to “an Equal-weight”. BMO Capital Markets began covering ACAD with “an Outperform” recommendation on June 27, 2024. Needham maintained its rating on March 12, 2024. It rated ACAD as “a Buy”.
Price Performance Review of ACAD
On Friday, Acadia Pharmaceuticals Inc [NASDAQ:ACAD] saw its stock jump 3.41% to $17.28. Over the last five days, the stock has gained 5.88%. Acadia Pharmaceuticals Inc shares have fallen nearly -44.81% since the year began. Nevertheless, the stocks have fallen -19.18% over the past one year. While a 52-week high of $32.59 was reached on 01/02/24, a 52-week low of $14.15 was recorded on 10/23/24. SMA at 50 days reached $15.71, while 200 days put it at $16.85.
Levels Of Support And Resistance For ACAD Stock
The 24-hour chart illustrates a support level at 16.89, which if violated will result in even more drops to 16.49. On the upside, there is a resistance level at 17.52. A further resistance level may holdings at 17.75. The Relative Strength Index (RSI) on the 14-day chart is 59.68, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.52, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 4.71%. Stochastics %K at 76.96% indicates the stock is a holding.
How much short interest is there in Acadia Pharmaceuticals Inc?
A steep rise in short interest was recorded in Acadia Pharmaceuticals Inc stocks on 2024-11-15, growing by 2.07 million shares to a total of 10.24 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 8.18 million shares. There was a rise of 20.19%, which implies that there is a positive sentiment for the stock.
